Health
Final Results from REPRISE III: Long-Term Stroke Risk after TAVR for Severe Aortic Stenosis – DocWire News
A study presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 Annual Meeting reported the final five-year results…
A study presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 Annual Meeting reported the final five-year results from the REPRISE III randomized trial, which assessed the Lotus Valve transcatheter aortic valve replacement (TAVR) system…
Continue Reading
-
Noosa News14 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business16 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400
-
General12 hours agoRescuers pull children from the rubble of Indonesian boarding school collapse
-
Business21 hours agoIs AustralianSuper buying or selling Telstra and CSL shares?